Navigation Links
Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR

ials of its product candidates, the Company's ability to develop a modified release formulation of CRx-102, potential difficulty and delays in obtaining regulatory approval for the sale and marketing of its product candidates, the Company's ability to obtain additional financing or funding for its research and development and those other risks that can be found in the "Risk Factors" section of the CombinatoRx Annual Report on Form 10-K on file with the Securities and Exchange Commission and the other reports that CombinatoRx periodically files with the Securities and Exchange Commission. Actual results may differ materially from those CombinatoRx contemplated by these forward-looking statements. CombinatoRx does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.

(c) 2007 CombinatoRx, Incorporated. All rights reserved.

Contact

CombinatoRx, Incorporated
Robert Forrester, 617-301-7100
EVP, Chief Financial Officer
rforrester@combinatorx.com
or
Gina Nugent, 617-301-7099
VP, Corporate Communications and IR
gnugent@combinatorx.com


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
4. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
5. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
6. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
7. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:7/6/2015)... -- Impax Laboratories, Inc. (NASDAQ: IPXL ) announced today ... financial results on Monday, August 10, 2015, prior to ... will host a conference call and live webcast with ... August 10, 2015. The financial results and ... section of the Company,s Web site at http://investors.impaxlabs.com ...
(Date:7/6/2015)... -- Mauna Kea Technologies (Euronext: MKEA, ... endomicroscopy platform, announced today it has obtained approval ... Health, Labor and Welfare (MHLW) for its unique ... miniprobe.   Used during endoscopy procedures, ... of a fiber-optic microscope that is small enough ...
(Date:7/6/2015)... , July 6, 2015  Protiviti, a global consulting ... Internal Auditing around the World publication ( www.protiviti.com/iaworld ... and reported on the evolution of the internal audit ... the globe as a means to providing senior executives ... this strategic business function. The 2015 edition ...
Breaking Medicine Technology:Impax to Report Second Quarter 2015 Results on August 10, 2015 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 3New Edition of Internal Auditing Around the World from Protiviti Explores Changes and Trends 2
... Trubion,s Proprietary ... Product Candidate, SBI-087 for RA Expands Trubion,s Family of Customized, Differentiated ... Product Candidates, ... has initiated a Phase 1/2,clinical trial of TRU-016, the company,s lead proprietary Small Modular,ImmunoPharmaceutical ...
... Encouraging Response in CF Patients - Results Validate ... March 27 The Cystic Fibrosis Foundation,announced today that ... defect in CF, showed promising results in an ongoing ... mutation of CF. The drug is,being developed by Vertex ...
Cached Medicine Technology:Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 2Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 3Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 4Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 5Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF 2Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF 3
(Date:7/7/2015)... ... July 07, 2015 , ... ... signs and safety labels, has been featured in the latest issue of In ... professionals. , In Compliance delivers the latest news, standards updates, technical ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... today announced they have been selected by the Department of Vermont Health Access ... its Medicaid Management Information System (MMIS) and Integrated Contact Center System project. , ...
(Date:7/6/2015)... ... July 07, 2015 , ... Currently, mobile ... incidence of AIDS, advances in the molecular diagnostic technologies, wide availability of immunosuppressive ... in detection technologies and genetic engineering also open lucrative opportunities for the market ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... eliminates 100% of all acids, chemicals and impurities; it also properly mineralizes the ... because it contains harmful contaminants.  These harmful contaminants are a byproduct of how ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... ... areas of orthopaedic sports medicine, the American Orthopaedic Society for Sports Medicine ( ... Meeting, July 9-12 in Orlando, FL. As a leader in orthopaedic sports ...
Breaking Medicine News(10 mins):Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 2Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 3Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 4Health News:CSG Government Solutions Selected by the Department of Vermont Health Access to Provide Quality Assurance and Independent Verification and Validation Services 2Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 2Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 3Health News:Pristine Water Filters.com Offers The 1st Water Revival System That Re-Mineralizes Drinking Water and Eliminates All Impurities and Chemicals 2Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 2Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 3Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 4Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 5Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 6
... two grants totaling more than $4.3 million from the ... pediatric pharmacology and vision research as part of SUNY ... health centers and the College of Optometry. The lead ... Downstate Medical Center in Brooklyn, New York. SUNY ...
... (QUT ) School of Nursing and Midwifery, in Brisbane, ... in self-managing their health and emotional concerns. Participants ... for ongoing information and emotional support, compared to those ... "There are a range of post-treatment effects people might ...
... alone in a laboratory, chemist Dan Shechtman looked through ... had discovered quasicrystals. But his groundbreaking findings were ... On October 5, 2011, Shechtman received the ... stand by his research? What drove the men and ...
... , FRIDAY, Oct. 14 (HealthDay News) -- ,Black and ... white children to receive a CT scan after they suffer ... examined the cases of nearly 40,000 children with head injuries ... about 35 percent of them underwent a cranial CT scan. ...
... One in six cellphones in Britain may be contaminated with ... many people don,t wash their hands properly after using the ... that many people lie about their hygiene habits, according to ... Medicine and Queen Mary, University of London. The study ...
... HealthDay Reporter , THURSDAY, Oct. 13 (HealthDay News) ... one killer, heart disease, continues to fall, according to new ... Overall, 6 percent of adults had heart disease in ... high blood pressure and high cholesterol, as well as declines ...
Cached Medicine News:Health News:SUNY receives $4.3 million for research in neuroscience, pediatric pharmacology and vision 2Health News:SUNY receives $4.3 million for research in neuroscience, pediatric pharmacology and vision 3Health News:Nurses boost well-being for cancer survivors 2Health News:How and why did 2011 Nobel winner Dan Shechtman persist despite rejection? 2Health News:1 in 6 Cellphones in Britain Contaminated With 'Fecal Matter' 2Health News:U.S. Heart Disease Rates Keep Falling: CDC 2Health News:U.S. Heart Disease Rates Keep Falling: CDC 3
The NexGen CR femoral component is intended for patients who, in the physician's judgement, have good bone stock and whose ligaments provide adequate mediolateral, anteroposterior, and varus/valgus s...
Cruciate retaining, posterior stabilized and constrained components....
The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results....
...
Medicine Products: